Alleviating pain with delta opioid receptor agonists: evidence from experimental models

J Neural Transm (Vienna). 2020 Apr;127(4):661-672. doi: 10.1007/s00702-020-02172-4. Epub 2020 Mar 18.

Abstract

The use of opioids for the relief of pain and headache disorders has been studied for years. Nowadays, particularly because of its ability to produce analgesia in various pain models, delta opioid receptor (DOPr) emerges as a promising target for the development of new pain therapies. Indeed, their potential to avoid the unwanted effects commonly observed with clinically used opioids acting at the mu opioid receptor (MOPr) suggests that DOPr agonists could be a therapeutic option. In this review, we discuss the use of opioids in the management of pain in addition to describing the evidence of the analgesic potency of DOPr agonists in animal models.

Keywords: Delta opioid receptor; G protein-coupled receptors; Pain; Primary afferents; Trafficking.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acute Pain* / drug therapy
  • Acute Pain* / metabolism
  • Analgesics, Opioid / pharmacology*
  • Animals
  • Cancer Pain* / drug therapy
  • Cancer Pain* / metabolism
  • Chronic Pain* / drug therapy
  • Chronic Pain* / metabolism
  • Humans
  • Migraine Disorders* / drug therapy
  • Migraine Disorders* / metabolism
  • Neuralgia* / drug therapy
  • Neuralgia* / metabolism
  • Receptors, Opioid, delta* / agonists
  • Receptors, Opioid, delta* / metabolism

Substances

  • Analgesics, Opioid
  • Receptors, Opioid, delta